{"id":"https://openalex.org/W3047741298","doi":"https://doi.org/10.1182/blood.v130.suppl_1.2909.2909","title":"Phase 2 Study of Brentuximab Vedotin in Patients with Advanced Systemic Mastocytosis","display_name":"Phase 2 Study of Brentuximab Vedotin in Patients with Advanced Systemic Mastocytosis","publication_year":2017,"publication_date":"2017-12-07","ids":{"openalex":"https://openalex.org/W3047741298","doi":"https://doi.org/10.1182/blood.v130.suppl_1.2909.2909","mag":"3047741298"},"language":"en","primary_location":{"id":"mag:3047741298","doi":"https://doi.org/10.1182/blood.v130.suppl_1.2909.2909","is_oa":false,"landing_page_url":"https://ashpublications.org/blood/article/130/Supplement%201/2909/80520/Phase-2-Study-of-Brentuximab-Vedotin-in-Patients","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Blood","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054770306","display_name":"John H. Baird","orcid":"https://orcid.org/0000-0001-8291-6546","observed_orcids":["https://orcid.org/0000-0001-8291-6546"]},"institutions":[{"id":"https://openalex.org/I4390039303","display_name":"Stanford Cancer Institute","ror":"https://ror.org/014qe3j22","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I4390039303","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John H. Baird","raw_affiliation_strings":["Division of Hematology, Stanford Cancer Institute, Stanford, CA"],"raw_orcid":"https://orcid.org/0000-0001-8291-6546","affiliations":[{"raw_affiliation_string":"Division of Hematology, Stanford Cancer Institute, Stanford, CA","institution_ids":["https://openalex.org/I4390039303","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085521139","display_name":"Sr\u0111an Verstov\u0161ek","orcid":"https://orcid.org/0000-0002-6912-8569","observed_orcids":["https://orcid.org/0000-0002-6912-8569"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sr\u0111an Verstov\u0161ek","raw_affiliation_strings":["Department of Leukemia  M. D. Anderson Cancer Center Houston, TX"],"raw_orcid":"https://orcid.org/0000-0002-6912-8569","affiliations":[{"raw_affiliation_string":"Department of Leukemia  M. D. Anderson Cancer Center Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015788207","display_name":"Tracy I. George","orcid":"https://orcid.org/0000-0001-5478-7847","observed_orcids":["https://orcid.org/0000-0001-5478-7847"]},"institutions":[{"id":"https://openalex.org/I169521973","display_name":"University of New Mexico","ror":"https://ror.org/05fs6jp91","country_code":"US","type":"education","lineage":["https://openalex.org/I169521973"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tracy I. George","raw_affiliation_strings":["Department of Pathology, University of New Mexico, Albuquerque, NM;"],"raw_orcid":"https://orcid.org/0000-0001-5478-7847","affiliations":[{"raw_affiliation_string":"Department of Pathology, University of New Mexico, Albuquerque, NM;","institution_ids":["https://openalex.org/I169521973"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033683887","display_name":"Isabel Reyes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039303","display_name":"Stanford Cancer Institute","ror":"https://ror.org/014qe3j22","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I4390039303","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Isabel Reyes","raw_affiliation_strings":["Division of Hematology, Stanford Cancer Institute, Stanford, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Stanford Cancer Institute, Stanford, CA","institution_ids":["https://openalex.org/I4390039303","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033281238","display_name":"Justin Abuel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039303","display_name":"Stanford Cancer Institute","ror":"https://ror.org/014qe3j22","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I4390039303","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Justin Abuel","raw_affiliation_strings":["Division of Hematology, Stanford Cancer Institute, Stanford, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Stanford Cancer Institute, Stanford, CA","institution_ids":["https://openalex.org/I4390039303","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070033945","display_name":"Cecelia Perkins","orcid":"https://orcid.org/0000-0002-1277-7699","observed_orcids":["https://orcid.org/0000-0002-1277-7699"]},"institutions":[{"id":"https://openalex.org/I4390039303","display_name":"Stanford Cancer Institute","ror":"https://ror.org/014qe3j22","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I4390039303","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cecelia Perkins","raw_affiliation_strings":["Division of Hematology, Stanford Cancer Institute, Stanford, CA"],"raw_orcid":"https://orcid.org/0000-0002-1277-7699","affiliations":[{"raw_affiliation_string":"Division of Hematology, Stanford Cancer Institute, Stanford, CA","institution_ids":["https://openalex.org/I4390039303","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110642887","display_name":"Cheryl Langford","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039303","display_name":"Stanford Cancer Institute","ror":"https://ror.org/014qe3j22","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I4390039303","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cheryl Langford","raw_affiliation_strings":["Division of Hematology, Stanford Cancer Institute, Stanford, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Stanford Cancer Institute, Stanford, CA","institution_ids":["https://openalex.org/I4390039303","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082794055","display_name":"Kurt Schroeder","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kurt Schroeder","raw_affiliation_strings":["Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065621786","display_name":"Jason R. Gotlib","orcid":"https://orcid.org/0000-0001-8253-6156","observed_orcids":["https://orcid.org/0000-0001-8253-6156"]},"institutions":[{"id":"https://openalex.org/I4390039303","display_name":"Stanford Cancer Institute","ror":"https://ror.org/014qe3j22","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I4390039303","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Gotlib","raw_affiliation_strings":["Division of Hematology, Stanford Cancer Institute, Stanford, CA"],"raw_orcid":"https://orcid.org/0000-0001-8253-6156","affiliations":[{"raw_affiliation_string":"Division of Hematology, Stanford Cancer Institute, Stanford, CA","institution_ids":["https://openalex.org/I4390039303","https://openalex.org/I97018004"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.3625,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.57894737,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"130","issue":null,"first_page":"2909","last_page":"2909"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11346","display_name":"Mast cells and histamine","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11346","display_name":"Mast cells and histamine","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11485","display_name":"Gastrointestinal Tumor Research and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brentuximab-vedotin","display_name":"brentuximab vedotin","score":0.9120000004768372},{"id":"https://openalex.org/keywords/systemic-mastocytosis","display_name":"systemic mastocytosis","score":0.8939999938011169},{"id":"https://openalex.org/keywords/cd30","display_name":"CD30","score":0.8489999771118164},{"id":"https://openalex.org/keywords/aggressive-systemic-mastocytosis","display_name":"aggressive systemic mastocytosis","score":0.843999981880188},{"id":"https://openalex.org/keywords/mast-cell-leukemia","display_name":"mast cell leukemia","score":0.8149999976158142},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.906000018119812},{"id":"https://openalex.org/keywords/monomethyl-auristatin-e","display_name":"monomethyl auristatin E","score":0.9599999785423279},{"id":"https://openalex.org/keywords/neoplastic-mast-cells","display_name":"neoplastic mast cells","score":0.6629999876022339},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.6959999799728394},{"id":"https://openalex.org/keywords/serum-tryptase","display_name":"serum tryptase","score":0.7170000076293945}],"concepts":[{"id":"https://openalex.org/C2780581156","wikidata":"https://www.wikidata.org/wiki/Q112670","display_name":"Systemic mastocytosis","level":3,"score":0.8869624733924866},{"id":"https://openalex.org/C2778191690","wikidata":"https://www.wikidata.org/wiki/Q422324","display_name":"Brentuximab vedotin","level":4,"score":0.6673011779785156},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6197109222412109},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5808749794960022},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.44529256224632263},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.34775710105895996},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.19023096561431885},{"id":"https://openalex.org/C2992779791","wikidata":"https://www.wikidata.org/wiki/Q209369","display_name":"Hodgkin lymphoma","level":3,"score":0.15084826946258545},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.09249043464660645}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:3047741298","doi":"https://doi.org/10.1182/blood.v130.suppl_1.2909.2909","is_oa":false,"landing_page_url":"https://ashpublications.org/blood/article/130/Supplement%201/2909/80520/Phase-2-Study-of-Brentuximab-Vedotin-in-Patients","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Blood","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2965316070","https://openalex.org/W2274220953","https://openalex.org/W2581645578","https://openalex.org/W2179483502","https://openalex.org/W2549335644","https://openalex.org/W2907191059","https://openalex.org/W2551960109","https://openalex.org/W4232569466","https://openalex.org/W2969347818","https://openalex.org/W2328519451"],"abstract_inverted_index":{"Abstract":[0],"BACKGROUND":[3],"Brentuximab":[5],"vedotin":[6],"(BV)":[7],"is":[8,27],"a":[9,30,148,179,187,203,225,313,473,484],"CD30-directed":[10],"antibody-drug":[11],"immunoconjugate":[12],"consisting":[13,617],"of":[14,65,81,160,205,227,245,253,268,291,385,397,412,421,436,475,563,571,579,611,618,668,696,826,840,853,868,884,908,923,940,954,970,986,1004],"an":[15,93,249,823,837,850,865,881,905,920,937,951,967,983,1001],"anti-CD30":[16],"antibody":[17],"and":[18,40,62,98,158,260,300,325,356,427,465,540,577,594,623,637,649,672],"the":[19,82,155,269,378,434,448,515,526,561],"microtubule":[20],"inhibitor":[21],"monomethyl":[22],"auristatin":[23],"E":[24],"(MMAE).":[25],"BV":[26,103,126,161,211,221,683],"approved":[28],"as":[29,47,49,85,110,112,472,582,584],"single":[31,535],"agent":[32],"for":[33,52,171,224,233,338,377,657,666],"relapsed/refractory":[34],"(R/R)":[35],"classical":[36],"Hodgkin":[37],"lymphoma":[38],"(cHL)":[39],"R/R":[41],"systemic":[42,75,87,90],"anaplastic":[43],"large":[44],"cell":[45,100,108],"lymphoma,":[46],"well":[48,111,583,685],"post-auto-HSCT":[50],"consolidation":[51],"high":[53],"risk":[54],"cHL.":[55],"Prior":[56],"studies":[57],"have":[58],"demonstrated":[59,186],"both":[60],"cytoplasmic":[61],"surface":[63],"expression":[64,262,302,494,548],"CD30":[66,261,301],"on":[67,178,431,822,836,849,864,880,904,919,936,950,966,982,1000],"neoplastic":[68,115],"mast":[69,99,134],"cells":[70,135],"(MC)":[71],"in":[72,106,113,162,293,505,519,534,558,693],"patients":[73,119,163,185,207,346,374,429,453,528,536,697],"with":[74,92,120,164,242,363,512,545,698],"mastocytosis":[76,88,91],"(SM),":[77],"including":[78],"advanced":[79,166,700],"forms":[80],"disease":[83,234,456,463],"such":[84],"aggressive":[86],"(ASM),":[89],"associated":[94],"hematologic":[95],"neoplasm":[96],"(SM-AHN),":[97],"leukemia":[101],"(MCL).":[102],"produced":[104],"apoptosis":[105],"CD30+":[107,121,133,165,493,506,546,699],"lines,":[109],"primary":[114,273],"MCs":[116],"derived":[117],"from":[118,132,483,603],"(but":[122],"not":[123,470,538,689],"CD30-)":[124],"SM.":[125,167,701],"also":[127],"downregulates":[128],"IgE-induced":[129],"histamine":[130],"release":[131],"(Blatt":[136],"et":[137,196],"al,":[138,197],"Blood,":[139,198],"2015).":[140],"METHODS":[144],"We":[146],"conducted":[147],"phase":[149],"2":[150,360,602],"investigator-initiated":[151],"study":[152,404],"to":[153,202,328,444,479,489,531,675],"evaluate":[154],"efficacy,":[156],"safety,":[157],"tolerability":[159],"The":[168,272,382,394,409,418,566,609],"goal":[169],"accrual":[170,201],"stage":[172],"1":[173,407,458,466,606],"was":[174,212,222,275,341,388,406,414,424,469,497,523,542,554,684],"11":[175],"patients.":[176],"Based":[177],"Simon":[180],"two-stage":[181],"design,":[182],"if":[183],"2/11":[184],"response":[188,192,246,277],"per":[189],"international":[190],"consensus":[191],"criteria":[193],"(IWG-MRT-ECNM;":[194],"Gotlib":[195],"2013),":[199],"further":[200],"total":[204,226],"26":[206],"would":[208],"be":[209],"undertaken.":[210],"dosed":[213],"at":[214,403,433],"1.8":[215],"mg/kg":[216],"intravenously":[217],"every":[218],"3":[219,349,633,644,647,651],"weeks.":[220],"administered":[223],"8":[228,251,451],"cycles,":[229],"or":[230,238,508,549,828,842,855,870,886,910,925,942,956,972,988,1006],"stopped":[231],"earlier":[232],"progression,":[235],"physician":[236],"discretion,":[237],"unacceptable":[239],"toxicity.":[240],"Responders":[241],"subsequent":[243],"loss":[244],"could":[247],"receive":[248],"additional":[250],"cycles":[252,423],"BV.":[254,490],"Bone":[255],"marrow":[256],"(BM)":[257],"biopsy":[258],"samples":[259],"were":[263,310,323,347,375,441,502,537,573,615,661],"centrally":[264],"reviewed":[265],"by":[266,303,312,495],"one":[267],"authors":[270],"(TIG).":[271],"endpoint":[274],"overall":[276],"rate":[278],"(ORR;":[279],"CR":[280],"+":[281,283],"PR":[282],"clinical":[284,669,691],"improvement":[285],"[CI]).":[286],"Secondary":[287],"endpoints":[288],"included":[289,628],"evaluation":[290],"changes":[292],"BM":[294,509,550],"MC":[295,507,510,547,551],"burden,":[296],"serum":[297,520],"tryptase":[298,521],"levels,":[299],"flow":[304,496],"cytometry.":[305],"Total":[306],"symptom":[307],"scores":[308],"(TSS)":[309],"assessed":[311],"modified":[314],"Myeloproliferative":[315],"Neoplasm":[316],"Symptom":[317],"Assessment":[318],"Form":[319],"(MPN-SAF).":[320],"Adverse":[321],"events":[322],"categorized":[324],"graded":[326],"according":[327,443],"CTCAE":[329],"4.03.":[330],"RESULTS":[334],"Data":[336],"cutoff":[337],"this":[339,694],"analysis":[340],"July":[342],"25,":[343],"2017.":[344],"10":[345,449,527],"enrolled;":[348],"ASM,":[350],"5":[351,425,630],"SM-AHN":[352],"(CMML-1,":[353],"n=3;":[354],"MDS/MPN-U":[355],"CEL,":[357],"each":[358],"n=1),":[359],"MCL":[361],"(one":[362],"CMML-1);":[364],"median":[365,383,395,410,419,517],"age":[366],"(range)":[367],"72.5":[368],"years":[369],"(40-84);":[370],"M:F":[371],"4:6;":[372],"all":[373],"positive":[376],"KIT":[379],"D816V":[380],"mutation.":[381],"number":[384,396,420],"prior":[386],"therapies":[387],"0.5":[389],"(0-2),":[390],"excluding":[391],"splenectomy":[392],"(n=3).":[393],"eligible":[398],"IWG-MRT-ECNM":[399,445],"organ":[400],"damage":[401],"findings":[402],"entry":[405],"(1-3).":[408],"duration":[411],"follow-up":[413],"114":[415],"days":[416],"(13-242).":[417],"treatment":[422,432,659],"(1-8),":[426],"two":[428],"remained":[430],"time":[435],"data":[437],"cutoff.":[438],"No":[439],"responses":[440],"observed":[442],"criteria.":[446],"Of":[447],"patients,":[450],"(80%)":[452],"had":[454,461],"stable":[455],"(SD);":[457],"(10%)":[459,467],"patient":[460,468,599],"progressive":[462],"(PD);":[464],"evaluable":[471],"result":[474],"early":[476,658],"death":[477,673],"due":[478,674],"intracranial":[480],"hemorrhage":[481],"(ICH)":[482],"mechanical":[485],"fall":[486],"considered":[487],"unrelated":[488],"Mean":[491],"baseline":[492,604],"67%":[498],"(range":[499,529],"29-96%).":[500],"There":[501,553],"no":[503,543,555],"reductions":[504],"burden":[511],"treatment.":[513,564],"Although":[514],"best":[516],"reduction":[518],"level":[522],"-29%":[524],"among":[525],"-5":[530],"-38%),":[532],"decreases":[533],"durable":[539],"there":[541],"correlation":[544],"burden.":[552],"significant":[556],"decrease":[557],"TSS":[559],"during":[560],"course":[562],"most":[567],"common":[568],"AEs":[569,614,627],"(regardless":[570],"attribution)":[572],"primarily":[574],"grade":[575,601,605,612,629,632,643,646,650],"1/2,":[576],"consisted":[578],"fatigue":[580],"(40%),":[581],"diarrhea,":[585],"abdominal":[586],"pain/discomfort,":[587],"infusion":[588],"reaction,":[589],"vomiting,":[590],"cough,":[591],"constipation,":[592],"dyspnea,":[593],"depression":[595],"(each":[596,654],"20%).":[597],"One":[598],"developed":[600],"peripheral":[607],"neuropathy.":[608],"majority":[610],"3/4":[613],"hematologic,":[616],"neutropenia":[619],"(30%),":[620],"anemia":[621],"(20%),":[622],"thrombocytopenia":[624],"(10%).":[625],"Serious":[626],"ICH,":[631],"altered":[634],"mental":[635],"status":[636],"portal":[638],"vein":[639],"thrombosis":[640],"(same":[641],"patient),":[642],"rash,":[645],"epiglottitis,":[648],"pleural":[652],"effusion":[653],"n=1).":[655],"Reasons":[656],"discontinuation":[660],"PD":[662],"(n=1),":[663],"investigator":[664],"discretion":[665],"lack":[667],"benefit":[670],"(n=3),":[671],"ICH":[676],"(n=1).":[677],"CONCLUSIONS":[681],"tolerated,":[686],"but":[687],"did":[688],"demonstrate":[690],"activity":[692],"cohort":[695],"Disclosures":[705],"Verstovsek:":[707],"Genentech:":[708,800],"Research":[709,712,717,721,724,727,731,734,738,742,746,750,755,758,763,768,771,774,777,780,783,786,789,793,798,801,804,809,812,816,831,845,858,873,889,892,896,899,913,928,931,945,959,975,978,991,995,1009],"Funding;":[710,713,718,722,725,728,732,735,739,743,747,751,756,759,764,769,772,775,778,781,784,787,790,794,799,802,805,810,813,832,846,859,874,890,893,897,900,914,929,932,946,960,976,979,992,996],"Pfizer:":[711,770],"CTI":[714,795,819,901],"BioPharma":[715,796],"Corp:":[716,762,797,808],"Seattle":[719,748,894,993],"Genetics:":[720,749,895,994],"Roche:":[723,811],"Incyte:":[726,803,833,947],"NS":[729,736],"Pharma:":[730,737],"Astrazeneca:":[733,757],"Lilly":[740,814],"Oncology:":[741,815],"Galena":[744,791],"BioPharma:":[745,792],"Bristol":[752,765],"Myers":[753,766],"Squibb:":[754,767],"Blueprint":[760,806,875,961],"Medicines":[761,807],"Celgene:":[773,779],"Promedior:":[776,785,898,977],"Gilead:":[782,788,847,980],"Funding.":[817,1010],"Gotlib:":[818],"Biopharma:":[820,902],"Membership":[821,835,848,863,879,903,918,935,949,965,981,999],"entity's":[824,838,851,866,882,906,921,938,952,968,984,1002],"Board":[825,839,852,867,883,907,922,939,953,969,985,1003],"Directors":[827,841,854,869,885,909,924,941,955,971,987,1005],"advisory":[829,843,856,871,887,911,926,943,957,973,989,1007],"committees,":[830,844,857,872,888,912,927,944,958,974,990,1008],"Honoraria,":[834,862,878,917,934,948,964,998],"Novartis:":[860,915],"Consultancy,":[861,877,916,963],"Medicines:":[876,962],"Pharmacyclics:":[891,930],"Deciphera:":[933,997]},"counts_by_year":[{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2020-08-13T00:00:00"}